Activated factor XI and tissue factor in chronic obstructive pulmonary disease: Links with inflammation and thrombin generation

• Published in: Thrombosis research Vol. 127; no. 3; pp. 242 - 246
• Main Authors: Jankowski, Milosz, Undas, Anetta, Kaczmarek, Przemyslaw, Butenas, Saulius
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Ltd 01.03.2011; Elsevier
• Subjects: Aged; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Chronic obstructive pulmonary disease; Coronary heart disease; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Factor XIa; Factor XIa - metabolism; Female; Heart; Hematology, Oncology and Palliative Medicine; Humans; Inflammation; Inflammation - complications; Male; Medical sciences; Middle Aged; Pulmonary Disease, Chronic Obstructive - complications; Pulmonary Disease, Chronic Obstructive - metabolism; Thrombin - metabolism; Thromboplastin - metabolism; Tissue factor; Chronic obstructive pulmonary disease; Inflammation; Factor XIa; Tissue factor; Lung disease; Serine endopeptidases; Enzyme; Respiratory disease; Cardiovascular disease; Thrombin; Peptidases; Factor XI; Hydrolases; Bronchus disease
• ISSN: 0049-3848; 1879-2472; 1879-2472
• DOI: 10.1016/j.thromres.2010.11.005

Increased cardiovascular mortality and risk of venous thromboembolism are serious extra-pulmonary complications of chronic obstructive pulmonary disease (COPD). Previously, circulating active tissue factor (TF) and factor XIa (FXIa) have been reported to be associated with acute coronary syndromes. To measure plasma FXIa and active TF, prothrombin fragment 1.2 (F1.2), and markers of systemic inflammation (C-reactive protein [CRP], interleukin-6 [IL-6], tumor necrosis factor α [TNFα] and matrix metalloproteinase 9 [MMP-9]) in 60 patients with documented stable COPD free of previous thromboembolic events. In-house clotting assays using inhibitory monoclonal antibodies against FXIa and TF. FXIa was detected in 9 (15%) and TF activity in 7 (11.7%) COPD patients. Subjects positive for FXIa and/or TF (n=10; 16.7%) had higher F1.2 (median [interquartile range], 398 [216] vs 192 [42] pM, p<0.000001), fibrinogen (5.58 [2.01] vs 3.97 [2.47] g/L, p=0.0007), CRP (14.75 [1.20] vs 1.88 [2.95] mg/L, p<0.000001), IL-6 (8.14 [4.74] vs 2.45 [2.24] pg/mL, p=0.00002), and right ventricular systolic pressure (47 [15] vs 38 [12] mmHg, p=0.023), and lower vital capacity (66 [15] vs 80 [17] % predicted, p=0.04) than COPD patients without detectable FXIa and TF. COPD severity was not associated with the presence of circulating FXIa and active TF. This is the first study to show that active FXIa and TF are present in stable COPD patients, who exhibit enhanced systemic inflammation and thrombin generation. Our findings suggest a new prothrombotic mechanism which might contribute to elevated risk of thromboembolic complications in COPD.